Corrixr Names Whiting Chair as CXR101 Nears Clinical Stage
NEWARK, DE — Corrixr Therapeutics appointed oncology drug-development executive Nancy Whiting as board chair as the preclinical genetic-medicine company prepares CXR101 for a regulatory filing and initial human testing in …
Corrixr Names Whiting Chair as CXR101 Nears Clinical Stage Read More